Clarivate™

Market Insights Summary

U.S. contrast agent and radiopharmaceutical market

What's trending and new

Theranostics and PSMA-PET imaging continue to accelerate radiopharmaceutical market growth

- Industry participants are increasing investments in theranostics platforms, PET production infrastructure, and targeted molecular imaging technologies to support the growing demand for precision diagnostics and personalized treatment approaches.
- Recent FDA approvals and indication expansions are accelerating the adoption of next-generation radiopharmaceuticals, while broadening the clinical use of PSMA-PET imaging across oncology applications and improving access to advanced diagnostic solutions.

Expanded CEUS indications are broadening adoption of ultrasound contrast imaging

- Regulatory approvals continue to expand the use of CEUS across a broader range of diagnostic applications, increasing the addressable patient population.
- Growing physician confidence in CEUS, coupled with its non-ionizing nature and strong safety profile, is supporting increased use across multiple imaging applications

Access more insights and data in the report. Speak to our team to see how we can power your innovation.

PSMA = Prostate-Specific Membrane Antigen
PET = Positron Emission Tomography
FDA = Food & Drug Administration
CEUS = Contrast-Enhanced Ultrasound
MRI = Magnetic Resonance Imaging
CT = Computed Tomography

2025 U.S. contrast agent and radiopharmaceutical market snapshot

$3.3B
Market revenue

3.5%
CAGR ('19-'35)

U.S. contrast agent and radiopharmaceutical market by product type



2025 U.S. competitive landscape



U.S. contrast agent and radiopharmaceutical procedures by product type



Competitor Insights

- Cardinal Health's leadership in the radiopharmaceuticals market is underpinned by its extensive distribution network and continued investments in theranostics and PET imaging capabilities.
- GE Healthcare remains the U.S. contrast agent market leader through its strong CT and X-ray contrast portfolio, vertically integrated manufacturing capabilities, and continued investment in product innovation and supply chain resilience.